Category: jama

Retract – and replace? JAMA may expand use of this tool

8b00ad69-1b6c-43bf-8626-22e8c5465ef0
Annette Flanagin

Remember last week, when JAMA replaced an article about the impact of moving homes on kids’ mental health after discovering some errors in the analysis? We’re going to see more of these somewhat unusual notices coming out of JAMA journals in the near future – the JAMA Network journals may   issue more “retract and replace” decisions for papers, in which it pulls an old version of an article and replaces it with a corrected one. But it’s not a correction — we spoke with Annette Flanagin, the Executive Managing Editor for The JAMA Network, to learn more. 

Retraction Watch: We’ve spotted three “retract and replace” notices in JAMA journals, including one issued earlier this year for a highly cited paper that contained “pervasive errors,” and the one last week about the impact of moving on kids’ mental health. How do you decide whether a paper will be retracted and replaced, or just retracted? Continue reading Retract – and replace? JAMA may expand use of this tool

JAMA authors retract (and replace) paper about moves and kids’ mental health

JAMAJAMA authors have retracted — and replaced — a 2014 paper about the mental health effects of household moves on kids, after they found errors while completing an additional analysis.

The original paper concluded that in “families who moved out of high-poverty neighborhoods, boys experienced an increase and girls a decrease in rates of depression and conduct disorder,” according to a press release issued by the journal along with the paper (which also got some press attention from Reuters). But part of that conclusion is wrong.

The authors write in a notice for “Associations of Housing Mobility Interventions for Children in High-Poverty Neighborhoods With Subsequent Mental Disorders During Adolescence” that:

Continue reading JAMA authors retract (and replace) paper about moves and kids’ mental health

JAMA: No plan to retract article on fetal pain, despite outcry from anti-abortion activists

JAMAJAMA has announced it does not intend to retract a 2005 review article about fetal pain, despite requests from anti-abortion activists who claim it has been misused in debates about the procedure.

Earlier this month, JAMA told one anti-abortion critic that it would take a look at the paper, which suggested that fetuses can’t feel pain before the third trimester. Critics have argued that newer findings have shown pain sensation appears earlier in gestation, yet the 2005 data continue to be cited in the discussion around abortion. What’s more, critics have lamented that some of the authors failed to mention their ties to the abortion industry.

But in a letter sent yesterday to James Agresti, Howard Bauchner, Editor in Chief at JAMA and The JAMA Network, writes: Continue reading JAMA: No plan to retract article on fetal pain, despite outcry from anti-abortion activists

Pro-lifers call for JAMA to retract 2005 paper about fetal pain

JAMAPro-life activists have asked JAMA to retract a 2005 paper that suggested fetuses can’t feel pain before the third trimester.

Critics are arguing that newer findings have shown pain sensation appears earlier in gestation, yet the 2005 data continue to be cited in the discussion around abortion. What’s more, they note, some of the authors failed to mention their ties to the abortion industry.

The 2005 paper has been cited 191 times, according to Thomson Reuters Web of Science. We spoke with Howard Bauchner, Editor in Chief at JAMA and The JAMA Network, who told us something similar to what he said last week, when PETA asked to retract a paper they claim could be harmful to elephants: Continue reading Pro-lifers call for JAMA to retract 2005 paper about fetal pain

JAMA journals pull 3 papers by same authors for misconduct

JAMAJAMA and another journal in its network have retracted three 2005 papers about preventing hip fractures, after an admission of scientific misconduct. 

All papers are being retracted over concerns about data integrity, and “inappropriate assignment of authorship.” Four of the authors — all based in Japan — have co-authored all of the three newly retracted papers, and also share authorship of a previous retraction from 2015. 

The JAMA paper was tagged with an Expression of Concern last year, regarding the “conduct, integrity, and scientific validity” of the paper. 

Here’s the retraction notice for the JAMA paper, “Effect of Folate and Mecobalamin on Hip Fractures in Patients With Stroke:” Continue reading JAMA journals pull 3 papers by same authors for misconduct

JAMA takes all calls for retraction seriously — even from PETA

JAMAA leading medical journal is taking a second look at a recent high-profile paper about elephants’ lower risk of cancer, after receiving a call for retraction from a somewhat unusual corner: the animal rights group PETA.

This isn’t the first time the activist group has called for a retraction — last year, it nudged a journal to pull a paper that had been flagged for fraud by the U.S. Office of Research Integrity. Their latest target: A 2015 paper in JAMA, which PETA claims contains inaccurate information.

What’s more, the organization argues, Ringling Bros and Barnum & Bailey Circus — which partly funded the research — is using the findings as “justification for the continued use of abusive training techniques with elephants.” Yesterday, PETA sent a letter to the journal asking it to either retract the paper or issue an expression of concern, claiming: Continue reading JAMA takes all calls for retraction seriously — even from PETA

Top journals give mixed response to learning published trials didn’t proceed as planned

Ben Goldacre
Ben Goldacre

Ben Goldacre has been a busy man. In the last six weeks, the author and medical doctor’s Compare Project has evaluated 67 clinical trials published in the top five medical journals, looking for any “switched outcomes,” meaning the authors didn’t report something they said they would, or included additional outcomes in the published paper, with no explanation for the change. The vast majority – 58 – included such discrepancies. Goldacre talked to us about how journals – New England Journal of Medicine (NEJM), JAMA, The Lancet, BMJ, and Annals of Internal Medicine — have responded to this feedback.

Retraction Watch: When you discover a published trial has switched outcomes, what do you do? Continue reading Top journals give mixed response to learning published trials didn’t proceed as planned

JAMA retracts osteoporosis paper with manipulated data

Screen Shot 2015-12-29 at 10.48.49 AMA JAMA study on an inexpensive treatment for osteoporosis has been retracted because the first author falsified or fabricated data. We’ve been expecting this one: An investigation at Women’s College Hospital in Toronto, the bone researcher’s former workplace, had already revealed issues with the paper.

An internal memo sent to staff (available in full here) in October explained that the investigation had found “unequivocal evidence of systematic data manipulation” by Sophie Jamal, who had already resigned from her positions at WCH and the University of Toronto.

The study appeared to show that nitroglycerin ointment could have a small positive effect on bone mineral density in postmenopausal patients. It’s been cited 30 times, according to Thomson Scientific’s web of Knowledge. (That’s two more times than when we last reported on the paper: It was cited once by the investigation, and once by a paper that was published earlier in October, but had not yet been indexed.)

Here’s the retraction note for “Effect of Nitroglycerin Ointment on Bone Density and Strength in Postmenopausal Women: A Randomized Trial:”

Continue reading JAMA retracts osteoporosis paper with manipulated data

Did a clinical trial proceed as planned? New project finds out

Ben Goldacre
Ben Goldacre

A new project does the relatively straightforward task of comparing reported outcomes from clinical trials to what the researchers said they planned to measure before the trial began. And what they’ve found is a bit sad, albeit not entirely surprising.

As part of The Compare Project, author and medical doctor Ben Goldacre and his team have so far evaluated 36 clinical trials published by the top five medical journals (New England Journal of Medicine, the Journal of the American Medical Association, The Lancet, Annals of Internal Medicine, and British Medical Journal). Many of those trials included “switched outcomes,” meaning the authors didn’t report something they said they would, or included additional outcomes in the published paper, with no explanation for the change.

Here are the latest results from the project, according to its website:

Continue reading Did a clinical trial proceed as planned? New project finds out

JAMA retracts second paper by heart researcher

Screen-Shot-2015-10-27-at-10.53.53-AMA heart researcher who fabricated trial participants has notched a second JAMA retraction. The retraction comes at the request of her co-authors, after an investigation by her former employer wasn’t able to confirm that this study was valid.

In September, we learned that Anna Ahimastos, who used to work at Baker IDI Heart and Diabetes Institute in Melbourne, Australia, had “fabricated [records] for trial participants that did not exist” in a JAMA trial for a blood pressure drug, according to principal investigator Bronwyn Kingwell.  That trial was retracted, along with a sub analysis.

An investigation by the institute found problems or sufficient doubt in several more publications. This second JAMA retraction is number 5 for Ahimastos, of 8 total expected.

The paper, “Effect of perindopril on large artery stiffness and aortic root diameter in patients with Marfan syndrome: a randomized controlled trial” Continue reading JAMA retracts second paper by heart researcher